BioSpecifics Technologies a biopharmaceutical company, has developed injectable collagenase (currently marketed as XIAFLEX in the U.S.) for 12 clinical indications. XIAFLEX is currently being marketed for the treatment of adult Dupuytren’s contracture patients with a palpable cord by Auxilium Pharmaceuticals in the U.S., and it is also approved for Dupuytren’s contracture in the European Union, Switzerland and Canada. XIAFLEX is additionally in clinical development to treat several other indications. For more information, visit the company’s Web site: http://www.biospecifics.com
Let us hear your thoughts below: